QUVIVIQ in patients with insomnia and comorbid anxiety, depression

• Research type

  Research Study

• Full title

  Retrospective, non-interventional multicenter study on the effect of QUVIVIQ in patients with insomnia disorder with comorbid anxiety and/or depression disorders

• IRAS ID

  357302

• Contact name

  David O'Regan

• Contact email

  david.o'regan@sleeplondon.com

• Sponsor organisation

  Idorsia Pharmaceuticals Ltd

• Duration of Study in the UK

  0 years, 3 months, 30 days

• Research summary

  QUVIVIQ has been approved in the EU and in the UK for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning. Patients with insomnia often have other medical conditions which coexist with the insomnia, like anxiety and depressive disorders. As there is limited knowledge on the effects of QUVIVIQ in patients with insomnia disorder and comorbid anxiety and/or depressive disorders, the researchers would like to collect data from patients who have already been treated with QUVIVIQ for their insomnia in clinical practice, and also have comorbid anxiety and/or depressive disorders. In this retrospective non-interventional study, the treatment with QUVIVIQ was done as per standard of care guidelines. There are no anticipated risks for the patients. Participants will be consented for the study, but they will not undergo any study related visits or procedures as the study is limited to data collection only.

• REC name

  Wales REC 6

• REC reference

  25/WA/0169

• Date of REC Opinion

  12 Jun 2025

• REC opinion

  Favourable Opinion